Abstract:BackgroundJamestown Canyon virus (JCV), family Bunyaviridae, is a mosquito-borne pathogen endemic in the United States and Canada that can cause encephalitis in humans and is considered an emerging threat to public health. The virus is genetically similar to Inkoo virus circulating in Europe, suggesting that much of the northern hemisphere contains JCV or similar variants.ResultsWe have completed the sequence of three isolates of JCV collected in geographically diverse locations over a 57 year time span. The n… Show more
“…Similarly, we did not detect JCV by RNA sequencing from acute serum and CSF from a third patient (Piantadosi et al, in preparation). While these were residual samples that may have been degraded by freeze/thaw cycles, our findings are consistent with prior results; JCV has never been isolated from human samples, and one study demonstrated no detectable viremia in experimentally infected rhesus macaques, despite seroconversion [34]. In general for orthobunyaviruses, it has been challenging to grow virus [35] or detect viral RNA in human samples; the few exceptions to this have included the detection of RNA from LACV in brain tissue [36], Oropouche virus in leukocytes [37], and Cache Valley virus in the CSF of an immunocompromised patient [38].…”
Jamestown Canyon virus (JCV) is a neuroinvasive arbovirus that is found throughout North America and increasingly recognized as a public health concern. From 2004 to 2012, an average of 1.7 confirmed cases were reported annually in the United States, whereas from 2013 to 2018 this figure increased over seventeen-fold to 29.2 cases per year. The rising number of reported human infections highlights the need for better understanding of the clinical manifestations and epidemiology of JCV. Here, we describe nine patients diagnosed with neuroinvasive JCV infection in Massachusetts from 2013, the year of the first reported case in the state, to 2017. Because current diagnostic testing relies on serology, which is complicated by cross-reactivity with related orthobunyaviruses and can be negative in immunosuppressed patients, we developed and evaluated an RT-qPCR assay for detection of JCV RNA. We tested this on the available archived serum from two patients, but did not detect viral RNA. JCV is transmitted by multiple mosquito species and its primary vector in Massachusetts is unknown, so we additionally applied the RT-qPCR assay and confirmatory RNA sequencing to assess JCV prevalence in a vector candidate, Ochlerotatus canadensis. We identified JCV in 0.6% of mosquito pools, a similar prevalence to neighboring Connecticut. We assembled the first Massachusetts JCV genome directly from a mosquito sample, finding high identity to JCV isolates collected over a 60year period. Further studies are needed to reconcile the low vector prevalence and low rate of viral evolutionary change with the increasing number of reported cases.
“…Similarly, we did not detect JCV by RNA sequencing from acute serum and CSF from a third patient (Piantadosi et al, in preparation). While these were residual samples that may have been degraded by freeze/thaw cycles, our findings are consistent with prior results; JCV has never been isolated from human samples, and one study demonstrated no detectable viremia in experimentally infected rhesus macaques, despite seroconversion [34]. In general for orthobunyaviruses, it has been challenging to grow virus [35] or detect viral RNA in human samples; the few exceptions to this have included the detection of RNA from LACV in brain tissue [36], Oropouche virus in leukocytes [37], and Cache Valley virus in the CSF of an immunocompromised patient [38].…”
Jamestown Canyon virus (JCV) is a neuroinvasive arbovirus that is found throughout North America and increasingly recognized as a public health concern. From 2004 to 2012, an average of 1.7 confirmed cases were reported annually in the United States, whereas from 2013 to 2018 this figure increased over seventeen-fold to 29.2 cases per year. The rising number of reported human infections highlights the need for better understanding of the clinical manifestations and epidemiology of JCV. Here, we describe nine patients diagnosed with neuroinvasive JCV infection in Massachusetts from 2013, the year of the first reported case in the state, to 2017. Because current diagnostic testing relies on serology, which is complicated by cross-reactivity with related orthobunyaviruses and can be negative in immunosuppressed patients, we developed and evaluated an RT-qPCR assay for detection of JCV RNA. We tested this on the available archived serum from two patients, but did not detect viral RNA. JCV is transmitted by multiple mosquito species and its primary vector in Massachusetts is unknown, so we additionally applied the RT-qPCR assay and confirmatory RNA sequencing to assess JCV prevalence in a vector candidate, Ochlerotatus canadensis. We identified JCV in 0.6% of mosquito pools, a similar prevalence to neighboring Connecticut. We assembled the first Massachusetts JCV genome directly from a mosquito sample, finding high identity to JCV isolates collected over a 60year period. Further studies are needed to reconcile the low vector prevalence and low rate of viral evolutionary change with the increasing number of reported cases.
“…We have previously demonstrated that JCV infection generates a neutralizing antibody response that also efficiently neutralizes both LACV and TAHV viruses (3,4). In the current study, we found that immunization with rJCV/LACV protected mice against lethal challenge with JCV, LACV, or TAHV.…”
Section: Discussionsupporting
confidence: 58%
“…JCV used in this study was a biological clone of the prototype strain 61V2235 (JCV/61/CO-cl) and previously sequenced and characterized (4). The recombinant LACV (rLACV) was generated from cDNA sequence of LACV strain 78 V 13193 (LACV/78/NC-cl) and was previously sequenced and characterized (5).…”
“…Interestingly, similar patterns of pathogenicity are observed in weanling mice inoculated with the CSG viruses known to cause human disease. Weanling mice are susceptible to disease from CEV, JCV, and INKV following IC or IN inoculation, but not following IP inoculation, indicating these viruses are neurovirulent, but not neuroinvasive, in mice [3,21,165]. LACV, SSHV, and TAHV all cause neuroinvasive disease in weanling mice following IP inoculation.…”
Section: Neuropathogenesis – Experimental Infections Of Animalsmentioning
confidence: 99%
“…In experimental infections of rhesus monkeys inoculated subcutaneously or intramuscularly with LACV, TAHV, or JCV, none of the monkeys developed disease [125,165,168]. However, nearly all monkeys developed high neutralizing antibody titers, indicating they were productively infected [125,165,168].…”
Section: Neuropathogenesis – Experimental Infections Of Animalsmentioning
The California serogroup (CSG) comprises 18 serologically and genetically related mosquito-borne orthobunyaviruses. Of these viruses, at least seven have been shown to cause neurological disease in humans, including the leading cause of pediatric arboviral encephalitis in the USA, La Crosse virus. Despite the disease burden from these viruses, much is still unknown about the CSG viruses. This review summarizes our current knowledge of the CSG viruses, including human disease and the mechanisms of neuropathogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.